electroCore, Inc.
NASDAQ:ECOR
electroCore, Inc.
Total Liabilities & Equity
electroCore, Inc.
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
electroCore, Inc.
NASDAQ:ECOR
|
Total Liabilities & Equity
$20.5m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Total Liabilities & Equity
$54.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
11%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Liabilities & Equity
$38.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Liabilities & Equity
$43B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Liabilities & Equity
$81.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Liabilities & Equity
$18.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
17%
|
|
electroCore, Inc.
Glance View
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
See Also
What is electroCore, Inc.'s Total Liabilities & Equity?
Total Liabilities & Equity
20.5m
USD
Based on the financial report for Dec 31, 2024, electroCore, Inc.'s Total Liabilities & Equity amounts to 20.5m USD.
What is electroCore, Inc.'s Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-10%
Over the last year, the Total Liabilities & Equity growth was 27%. The average annual Total Liabilities & Equity growth rates for electroCore, Inc. have been -22% over the past three years , -10% over the past five years .
You don't have any saved screeners yet